Tagged with Netherlands

pharma CEO of Pantarhei since its inception in 2001, Herjan Coelingh Bennink outlines the company’s vision to develop new applications for existing compounds in the fields of women’s health and oncology with therapies with real medical advantages including a contraceptive pill which does not increase the risk of thrombosis and improved…

pharma The CEO of BioConnection, the leading contract services and manufacturing organization for the development and production of injectable (bio)pharmaceutical products, explains how —thanks to flexibility and quality-driven mentality —the company helps small and medium biotech companies and universities make their products reality. This year BioConnection celebrates its tenth anniversary and…

pharma The Netherlands provides a flourishing environment for biotech to grow. The vice president for European operations at Kite Pharma discusses how biotech start-ups can find their path to success and how Kite Pharma is looking at new innovative therapies for cancer treatment. Before joining T-Cell Factory, later acquired by Kite…

pharma IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his perspective about the Dutch healthcare and life sciences market, the challenges it poses and what companies can expect for the…

pharma Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success. In 2014/2015, three Dutch biotechs (UniQure, ProQR, Galapagos) went public on Nasdaq, and…

pharma Lygature is the new name of TI Pharma and CTMM, two internationally renowned public-private-partnerships turned non-for-profit partnership drivers. Managing Director Jorg Janssen explains that it will be business as usual for the merged organization, but with more opportunities for cross-disciplinary collaborations than ever before. Lygature drives partnerships for the development of…

pharma The Centre for Human Drug Research provides a full range of early stage clinical pharmacology services. The CEO discusses the vision behind the creation of the foundation as well as some of its most recent educational and funding initiatives destined to help biotech companies develop new drugs. You founded the…

Pharma Michel van Agthoven outlines the role played by the Pharmaceutical Committee of the American Chamber in contributing to healthcare related policies in the Netherlands through research programs and by encouraging collaboration between stakeholders. The Committee aims to contribute to the improvement of key aspects of the healthcare system in the…

Pharma Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than the symptoms of this disease and the current research climate in the Netherlands. Introduction to Bart Roep and his current…

Pharma Frank Grosveld, Professor of Molecular Biology at Erasmus Medical Center, tells PharmaBoardroom about how Dutch research and development environment has evolved over recent decades.  Frank, to begin could you please introduce yourself to our readers around the world, with reference to your current research interests and educational responsibilities? I am…

Pharma OrganoPlates™ serve as a highly useable platform for 3D cell cultures, are completely compatible with existing lab equipment, and can be used to develop true ‘organ-on-a-chip’ models. Co-founders of the developer and manufacturer, Mimetas, discuss the impact this product is already having on the drug development process, and its potential…

Pharma Michel Dutree, former director general of the Dutch association for pharmaceutical innovators, gives a detailed overview of the changes happening in the Dutch pharmaceutical industry, and the Netherlands’ role at the European level as the “laboratory of Europe.” It’s been four years since your last interview with PBR; what do…